The Pre-Diligence Discipline

The 2026 capital environment for medical device companies is structurally less forgiving than the one most founders raised into a few years ago. Total healthcare venture investment fell to $46.8B in 2025, a 12% decline from the year prior, and SVB has characterized the moment as a 'fundraising reset' in which earlier capital is concentrating around companies that can demonstrate clinical validation, revenue traction, or capital-efficient business models.^[1]

Inside that tighter environment, a quiet structural problem in how medtech investors evaluate companies has become a meaningful drag on outcomes — for founders and investors alike. Medtech due diligence is, by long-standing convention, technology-first. Commercial story validation runs distantly behind, often deferred until after technical and regulatory criteria are satisfied.^[2] In a generous capital environment, that sequencing was tolerable. In this one, it is the difference between a closed round and a passed deal — or worse, a closed round followed by twelve months of post-raise commercial drag that the investor and founder discover together.

This brief argues that medtech founders preparing to raise should adopt a discipline that adjacent industries — pharma licensing, private equity, biotech buy-side diligence — have practiced for decades: pre-diligence. A structured, internal pressure-test of the commercial story before it meets an outside evaluator. The practice is not novel. It is simply not yet standard in medtech, and the founders who treat it as standard will increasingly outperform the founders who do not.

Here is the structural problem. Medtech investor diligence, as practiced today, is sequenced in a way that systematically de-prioritizes the commercial story.

In a 2024 analysis published in Medical Product Outsourcing, life sciences attorney Robert H. Underwood of Faegre Drinker Biddle & Reath described the industry's prevailing diligence pattern directly: medtech diligence focuses first on the technology's promise for improving patient outcomes and other clinical metrics, with attention shifting to the competitive landscape and reimbursement only after that initial criterion is satisfied.^[2] Underwood is not describing a flaw — he is describing the standard. And he goes on to argue that the standard is increasingly inadequate, urging buyers and investors to consider end-game issues such as reimbursement and commercialization earlier in their planning, since market players often focus heavily on the science itself and pay less attention to supply chain, intellectual property, and reimbursement realities.^[2]

The angel investor view confirms the pattern from the other side of the table. In a published account of the diligence process at Robin Hood Ventures, a Philadelphia-based angel group, certain commercial themes emerge 'repeatedly' because so many startups arrive without having addressed them.^[4] Among the recurring failures: top-down market sizing extrapolated from inflated industry reports without bottom-up validation; clinician testimonials shaped by confirmation bias rather than honest critique; and unsubstantiated claims about VC interest in the next round that diligence teams routinely verify by direct conversation.^[4]

Investors are not unaware of the commercial questions. The pattern is that they often arrive at those questions late, with limited time, and through a screening process that was not designed to surface the answers in depth. Commercial diligence in medtech, where it happens at all, tends to live in three places: reimbursement review, typically focused on whether codes exist and whether the company has a defensible coding strategy^[5]; market sizing review, typically a sanity check on TAM/SAM/SOM rather than a bottom-up validation of who actually buys, who signs, and how long the cycle runs^[4]; and reference calls, which can be illuminating but are constrained by the network the investor already has access to.

What is rarely evaluated with rigor: the coherence of the commercial narrative under pressure. Whether the buyer story holds up when an outside evaluator probes the buying committee. Whether the evidence package matches the actual decision threshold of the institution making the purchase. Whether the sequencing of the commercial plan — what gets built, sold, and proven in what order — is internally consistent or quietly aspirational.

The gap is not that investors don't care about these questions. It is that the diligence process, as conventionally structured, is not built to answer them well. And the founder is the one who pays the cost when the answers turn out to be wrong.

The discipline of running an internal commercial review before exposing a company to outside diligence is not an invention. It is a long-standing practice in adjacent sectors of life sciences and in private equity. Medtech is the conspicuous outlier.

In pharma and biotech, the practice is explicit. Alacrita, a life sciences advisory firm that has conducted more than 350 due diligence assignments, recommends in its published guidance that companies consider running a focused internal due diligence process — preferably using an external diligence team — before exposing the company to formal diligence by investors, acquirers, or licensors.^[9] The rationale is straightforward: it is better to find the problems on your own terms than to have them surfaced by a counterparty with leverage. Alacrita also notes that staged diligence offers material process efficiencies, since a small pre-DD team can identify critical issues without the time and expense of a full documentation review, and any showstoppers can be addressed before a formal process begins.^[9]

In private equity, commercial due diligence is so standard that it has its own institutional shape. Plante Moran, in its 2025 platform-acquisition diligence guidance, describes commercial diligence as the practice that validates the investment thesis, quantifies the gap between current capabilities and market potential, and identifies the strategic levers required for success — including organizational upgrades, sales force optimization, new growth markets, and product innovations. Without this lens, the firm warns, private equity buyers risk underestimating capability constraints or overestimating market tailwinds, leading to missed growth targets and reduced exit multiples.^[10] The buy-side view of commercial diligence is that it is non-optional. It is one of the standard diligence disciplines a serious capital partner runs before committing to a deal.

The asymmetry, then, is structural. In pharma, pre-diligence is a recommended seller-side practice. In private equity, commercial diligence is a required buy-side practice. In medtech, neither side reliably runs a rigorous commercial story review before capital is committed. The founder is the party with the most to lose, and the founder is the party best positioned to close the gap by running the work themselves.

In a constrained capital environment, the founder who has run their own commercial story through a pre-diligence review walks into the investor conversation differently. Not because they have a better story — though they often do — but because they have already met their story's weak points and know how they will answer when those points are pressed.

This is the practical case for pre-diligence as a discipline. The macroeconomic argument is real: capital is tighter, evaluators are more selective, and commercial fundamentals carry more weight than they did three years ago.^[1] The structural argument is real: medtech diligence under-evaluates commercial readiness, and the cost shows up after the round closes.^[2][8] But the case that lands hardest with a founder is the simplest one. Most medtech founders are technical leaders, clinicians, or operators who built the company around a real innovation. They are typically not commercial-first builders, and the commercial story is the part of the company they have least reason to trust their own judgment on.

Pre-diligence is the discipline of surfacing that uncertainty on your own terms, while you still have time to address it, rather than discovering it across the table from a partner who has leverage you do not.

The medtech industry has always rewarded the discipline of getting the technology right. The next decade will increasingly reward the discipline of getting the commercial story right at the same level of rigor — and pre-diligence is the practice through which that rigor is built.